Company news

Dimerix Limited news in 2023

Dimerix Limited's news releases, calls and decks from 2023, newest first.

View company

ACTION3 IND Approved in China

November 27, 2023

Dimerix Receives Initial Upfront Payment from Advanz Pharma

November 5, 2023

Dimerix Announces License Agreement for EU, Canada, ANZ

October 4, 2023

FDA Approves Qytovra Brand Name

September 24, 2023

Regulatory Approval received in Malaysia for ACTION3 Study

September 21, 2023

Dimerix Receives $8.9M R&D Tax Incentive Rebate

September 12, 2023

Successful Completion of 2nd DSMB Review of FSGS Trial

August 7, 2023

DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24

July 23, 2023

Approval received for Paediatric Investigation Plan from EMA

July 4, 2023

Dimerix confirms Phase 3 study design appropriate for China

July 2, 2023

Prospectus

June 26, 2023

Dimerix Announces Update on Successful Capital Raise

June 5, 2023

Rights Issue Prospectus

May 4, 2023

Reinstatement to Official Quotation

May 3, 2023

Entitlement offer and Convertible Note to raise $12 million

May 3, 2023

Voluntary Suspension

May 2, 2023

Half-Year Financial Report & Appendix 4D - 31 December 2022

February 26, 2023

DXB to Receive $2.8m in Prepayment of R&D Tax Incentive

February 16, 2023

Successful Completion of DSMB Review of Phase 3 FSGS Trial

February 8, 2023

FDA Confirms Inclusion of Paediatrics in ACTION3 Study

January 11, 2023

Decks in 2023